tislelizumab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Esophageal Carcinoma

Pending FDA approval for unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had received prior systemic therapy

Next:

Pharmacology

Mechanism of Action

Humanized IgG4 anti-PD-1 monoclonal antibody

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.